group VI iPLA₂ Antibody (D-4): sc-376563

group VI iPLA2 Antibody (D-4) is a mouse monoclonal IgG1 kappa light chain antibody that detects group VI iPLA2 of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). group VI iPLA2 Antibody (D-4) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. group VI iPLA2 plays a crucial role in lipid metabolism by catalyzing the release of fatty acids from phospholipids, which is essential for maintaining cellular membrane integrity and signaling pathways. Notably, group VI iPLA2 is membrane-bound and exists in several isoforms due to alternative splicing, with two isoforms, Ankyrin-iPLA2-1 and -2, lacking the catalytic domain and believed to negatively regulate iPLA2 activity. The SH-iPLA2 isoform is localized in the cytoplasm, highlighting the diverse functional roles of iPLA2 in cellular processes. The human gene encoding iPLA2 is located on chromosome 22q13.1, and iPLA2′s interaction with other phospholipases, such as secretory phospholipases A2, underscores iPLA2′s importance in the broader context of phospholipid metabolism and eicosanoid biosynthesis.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

group VI iPLA₂ Antibody (D-4) References:

1. Human pancreatic islets express mRNA species encoding two distinct catalytically active isoforms of group VI phospholipase A2 (iPLA2) that arise from an exon-skipping mechanism of alternative splicing of the transcript from the iPLA2 gene on chromosome 22q13.1.  |  Ma, Z., et al. 1999. J Biol Chem. 274: 9607-16. PMID: 10092647
2. The human calcium-independent phospholipase A2 gene multiple enzymes with distinct properties from a single gene.  |  Larsson Forsell, PK., et al. 1999. Eur J Biochem. 262: 575-85. PMID: 10336645
3. I-PLA(2) activation during apoptosis promotes the exposure of membrane lysophosphatidylcholine leading to binding by natural immunoglobulin M antibodies and complement activation.  |  Kim, SJ., et al. 2002. J Exp Med. 196: 655-65. PMID: 12208880
4. iPLA2 inhibitor blocks negative inotropic effect of HIV gp120 on cardiac myocytes.  |  Kan, H., et al. 2006. J Mol Cell Cardiol. 40: 131-7. PMID: 16316660
5. Role of iPLA2 and store-operated channels in agonist-induced Ca2+ influx and constriction in cerebral, mesenteric, and carotid arteries.  |  Park, KM., et al. 2008. Am J Physiol Heart Circ Physiol. 294: H1183-7. PMID: 18156193
6. Structures of free and inhibited human secretory phospholipase A2 from inflammatory exudate.  |  Scott, DL., et al. 1991. Science. 254: 1007-10. PMID: 1948070
7. Antipsychotic drugs decrease iPLA2 gene expression in schizophrenia.  |  Kerr, DS., et al. 2013. Schizophr Res. 147: 203-204. PMID: 23587695
8. Low platelet iPLA₂ activity predicts conversion from mild cognitive impairment to Alzheimer's disease: a 4-year follow-up study.  |  Gattaz, WF., et al. 2014. J Neural Transm (Vienna). 121: 193-200. PMID: 24036895
9. PKCδ-iPLA2-PGE2-PPARγ signaling cascade mediates TNF-α induced Claudin 1 expression in human lung carcinoma cells.  |  Iitaka, D., et al. 2015. Cell Signal. 27: 568-77. PMID: 25562426
10. Increased iPLA2 activity and levels of phosphorylated GSK3B in platelets are associated with donepezil treatment in Alzheimer's disease patients.  |  Talib, LL., et al. 2015. Eur Arch Psychiatry Clin Neurosci. 265: 701-6. PMID: 25920742
11. Cloning, chromosomal mapping, and expression of a novel human secretory phospholipase A2.  |  Cupillard, L., et al. 1997. J Biol Chem. 272: 15745-52. PMID: 9188469
12. Crystal structure of human secretory phospholipase A2-IIA complex with the potent indolizine inhibitor 120-1032.  |  Kitadokoro, K., et al. 1998. J Biochem. 123: 619-23. PMID: 9538252

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-group VI iPLA₂ Antibody (D-4) has 10 citations in a variety of scientific publications.

Primary antibodies like Anti-group VI iPLA₂ Antibody (D-4) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

group VI iPLA₂ Antibody (D-4) Specifications

Alternate Product Name: group VI iPLA2

Product Clone Name: D-4

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 727-759

Epitope Target: iPLA2

Epitope Species: human

Product Reactivity/Detection: calcium-independent PLA₂

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: equine, canine, bovine and porcine

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 10 citations in various scientific publications

Available Conjugates/Forms for group VI iPLA₂ Antibody (D-4): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, P: Blocking Peptide, PE: Phycoerythrin